BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination

WALTHAM, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today its receipt of a favorable decision from the Listing Qualifications Department (the "Staff") of The NASDAQ Stock Market LLC ("NASDAQ"), which granted the Company's request for continued listing on NASDAQ, pursuant to an extension within which to evidence compliance with NASDAQ Listing Rule 5550(b) (the "Rule"). In the Company's case, the Rule requires the Company to evidence either a minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million. The Company is diligently working to evidence compliance with the Rule on or before May 19, 2015, as required by the Staff.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit

The BG Medicine Inc. logo is available for download here.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our ability to evidence compliance with the NASDAQ continued listing rules on or before the date required by NASDAQ. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading "Risk Factors" contained in BG Medicine's annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

CONTACT: Stephen Hall, EVP & Chief Financial Officer (781) 890-1199

Source:BG Medicine, Inc.